Skip to main content
Equibles
HRMY logo

HRMY · Harmony Biosciences Holdings, Inc. · Earnings Call Transcripts & Audio

Track HRMY — free

Use HRMY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HRMY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.26 -0.03 (-0.08%) At close · Sep 30
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.40B
Shares
58.24M
Volume · Sep 30 667.69K Avg daily vol (3M) 886.01K

Harmony Biosciences Holdings, Inc. Earnings Call Transcripts

Quarterly earnings calls for Harmony Biosciences Holdings, Inc. (HRMY), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲45.2% $117.21M $87.94M '22 Q3 22-11-01 ▲40.7% $128.31M $48.51M '22 Q4 23-02-21 ▲39.6% $119.13M $29.48M '23 Q1 23-05-02 ▲25.4% $134.22M $34.30M '23 Q2 23-08-01 ▲36.7% $160.27M $38.46M '23 Q3 23-10-31 ▲31.3% $168.41M $26.61M '23 Q4 24-02-22 ▲29.8% $154.62M $38.33M '24 Q1 24-04-30 ▲28.8% $172.81M $11.59M '24 Q2 24-08-06 ▲16.1% $186.04M $46.09M '24 Q3 24-10-29 ▲19.5% $201.27M $49.48M '24 Q4 25-01-13 ▲19.5% $184.73M $45.56M '25 Q1 25-05-06 ▲16% $200.49M $39.78M '25 Q2 25-08-05 ▲28.7% $239.46M $50.87M '25 Q3 25-11-04 ▲21.1% $243.78M $22.49M '25 Q4 26-02-24 ▲16.6% $215.39M $32.49M '26 Q1 26-05-07 LATEST ▲30.3% $261.28M $75.43M '26 Q2 26-08-04
Earnings call
FY26 · Q2
2026-08-04
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
Confident tone Phase 1 PK and safety data for BP-205 WAKIX commercial performance and revenue growth Upcoming data catalysts
Revenue
$261.28M
▲ 30.3% YoY
Diluted EPS
$1.28
▲ 88.2% YoY
Gross margin
75.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Harmony Biosciences Holdings, Inc. (HRMY) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call
Revenue
$215.39M
▲ 16.6% YoY
Diluted EPS
$0.55
▼ 29.5% YoY
Gross margin
79.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-13
Harmony Biosciences Holdings, Inc. (HRMY) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Confident tone Late-stage pipeline and clinical catalysts WAKIX commercial performance and blockbuster guidance Pediatric narcolepsy approval and expansion
Revenue
$243.78M*
▲ 21.1% YoY
Gross margin
71.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Confident tone Pitolisant HD next-gen formulation WAKIX commercial momentum Pipeline setbacks and confidence
Revenue
$239.46M
▲ 28.7% YoY
Diluted EPS
$0.87
▲ 10.1% YoY
Gross margin
75.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Earnings Call Transcript
Confident tone Pipeline and late-stage catalysts WAKIX commercial performance Fragile X / ZYN002 opportunity
Revenue
$200.49M
▲ 16% YoY
Diluted EPS
$0.68
▲ 240% YoY
Gross margin
81.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
Confident tone WAKIX commercial performance in narcolepsy ZYN002 in Fragile X Syndrome (RECONNECT) Pitolisant HD next-generation formulation
Revenue
$184.73M
▲ 19.5% YoY
Diluted EPS
$0.78
▲ 16.4% YoY
Gross margin
82.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2024 Earnings Call Transcript
Confident tone Pitolisant HD (next-generation) development ZYN002 Fragile X program Idiopathic Hypersomnia (IH) sNDA setback
Revenue
$201.27M*
▲ 19.5% YoY
Gross margin
73.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call Transcript
Confident tone Rare epilepsy franchise (EPX-100, EPX-200) Pitolisant franchise lifecycle (IH, GR, HD) Late-stage pipeline and launches
Revenue
$186.04M
▲ 16.1% YoY
Diluted EPS
$0.79
▲ 25.4% YoY
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2024 Earnings Call Transcript
Confident tone WAKIX commercial performance Pediatric narcolepsy launch Pitolisant HD / life-cycle management
Revenue
$172.81M
▲ 28.8% YoY
Diluted EPS
$0.20
▼ 64.3% YoY
Gross margin
81.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2024 Earnings Call Transcript
Confident tone TPM-1116 orexin-2 receptor agonist WAKIX commercial performance Pitolisant life cycle management & new indications
Revenue
$154.62M
▲ 29.8% YoY
Diluted EPS
$0.67
▲ 39.6% YoY
Gross margin
82.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript
Confident tone WAKIX commercial growth and durability Next-generation pitolisant formulations Pediatric narcolepsy sNDA and pediatric exclusivity
Revenue
$168.41M*
▲ 31.3% YoY
Gross margin
74.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2023 Earnings Call Transcript
Revenue
$160.27M
▲ 36.7% YoY
Diluted EPS
$0.63
▼ 56.2% YoY
Gross margin
79.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Transcript
Revenue
$134.22M
▲ 25.4% YoY
Diluted EPS
$0.56
▲ 43.6% YoY
Gross margin
81.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2023 Earnings Call Transcript
Revenue
$119.13M
▲ 39.6% YoY
Diluted EPS
$0.48
▲ 37.1% YoY
Gross margin
82.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2022 Earnings Call Transcript
Revenue
$128.31M*
▲ 40.7% YoY
Gross margin
79.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2022 Earnings Call Transcript
Revenue
$117.21M
▲ 45.2% YoY
Diluted EPS
$1.44
Gross margin
80.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2022 Earnings Call Transcript
Revenue
$107.03M
▲ 45% YoY
Diluted EPS
$0.39
▲ 62.5% YoY
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2022 Earnings Call Transcript
Revenue
$85.31M
▲ 43% YoY
Diluted EPS
$0.35
▲ 169.2% YoY
Gross margin
82.8%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2021 Earnings Call Transcript
Revenue
$91.21M*
▲ 62% YoY
Gross margin
80.5%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2021 Earnings Call Transcript
Revenue
$80.73M
▲ 77% YoY
Diluted EPS
$-0.17
Gross margin
81.9%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2021 Earnings Call Transcript
Revenue
$73.82M
▲ 94.2% YoY
Diluted EPS
$0.24
Gross margin
82.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2021 Earnings Call Transcript
Revenue
$59.67M
▲ 200.8% YoY
Diluted EPS
$0.13
Gross margin
82.6%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2020 Earnings Call
Revenue
$56.29M*
Gross margin
82.4%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2020 Earnings Call
Revenue
$45.61M
Diluted EPS
$-0.14
Gross margin
82.7%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts CIK 1802665 CUSIP 413197104 13F (30d) 10 filings 8 filers Visit website Investor relations